You are here
- Dr. Ludwin highlights sessions from ACTRIMS Forum 2016. Mitochondrial abnormalities contribute to axonal pathology in MS. Additionally, there is some...
Interview with Ludwig Kappos: Predictive value of NEDA for disease outcome over 6 years in patients with RRMSAccording to Professor Kappos, there was an increasing need to have a comprehensive summarising outcome when comparing different clinical trials...
Gabriele de LucaDr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.
Laura AirasIn her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
Elga de VriesMicroglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective.